BiotechTube
Home/Guard Therapeutics/Tobias Agervald
TA

Tobias Agervald

Chief Executive Officer

Guard Therapeutics

Therapeutic Areas

NephrologyKidney Disease

Guard Therapeutics Pipeline

DrugIndicationPhase
RMC-035 (G002)Prevention of Acute Kidney Injury (AKI) after major cardiovascular surgeryPhase 2